European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial...
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial...
Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia...
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and...
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with...
Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare...
Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza®...
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads